Phase 3 topline
Primary completion of ABTECT - Maintenance
AAVXF · Abivax S.A. · ABX464 · Ulcerative Colitis
Resolved
Success on 2026-09-21, state resolved.
Sources and detail
- Float
- No public float has been reported at a usable date.
- Stake
- Research for this company needs an account. The sample companies are fully interactive without one.
- Runway vs event
- Cash or burn is missing, so no runway verdict is made.
- Financing
- No financing filing in the period covered.
- Specialist holders
- No specialist 13F quarter has been read for this issuer.
- Insider net 90d
- No open-market insider transaction was filed in the window.
What happened
Success · 2026-09-21.
This event resolved, on the document and quote below.
Sources (2)
- ClinicalTrials.gov · NCT05535946
clinicaltrials gov · published 2026-07-07 · retrieved 2026-09-21
“primaryCompletionDateStruct: {"date": "2026-04-28", "type": null}”
- SEC EDGAR
sec filing · published 2026-09-21 · retrieved 2026-09-22
“On June 1, 2026 , we announced positive results from Part 1 of the Phase 3 ABTECT 44-week maintenance trial, demonstrating strong efficacy, including robust endoscopic remission, and on June 29, 2026, we announced positive topline results from Part 2 of the maintenance trial.”
Research
This event is not joined to a researched indication.
Research date unknown
Market
Market linking is switched off.
Quotes elsewhere
This desk holds no price. These go to the venues that publish one.
What counts as each outcome
Resolved by the sponsor's topline disclosure of the trial's primary endpoint: met with statistical significance is success; missed is failure; co-primary endpoints split, or significance reached only in a pre-specified subgroup, is mixed.
Missing inputs
- issuer_facts: not collected
- public_float_usd: not collected
- shares_outstanding: not collected
- cash_and_investments: not collected
- operating_cash_flow: not collected
- quarterly_burn: not collected
- runway_quarters: not collected
Event row last changed 2026-09-22 · filing signals evaluated 2026-09-22
What changed on this event
- — · created · event · — → Primary completion of ABTECT - Maintenance · clinicaltrials_gov-candidate
- — · status · review_state · pending → published · government-source
- — · date passed · resolution_state · not_watched → date_passed · Guided window closed 86 days ago with no announcement.
- — · resolved · status · upcoming → resolved · verified against the primary 6-K (2026-06-02, accession 0001193125-26-252360): obefazimod met the FDA primary endpoint of placebo-adjusted clinical remission at Week 44 in both the 25mg (p<0.0001) and 50mg (p<0.0001) arms of ABTECT Part 1; June 29 6-K (Part 2) reports exploratory non-responder/relapser data only, not the primary readout; resolving success on the Part 1 primary-endpoint result
- — · resolved · outcome · — → success · verified against the primary 6-K (2026-06-02, accession 0001193125-26-252360): obefazimod met the FDA primary endpoint of placebo-adjusted clinical remission at Week 44 in both the 25mg (p<0.0001) and 50mg (p<0.0001) arms of ABTECT Part 1; June 29 6-K (Part 2) reports exploratory non-responder/relapser data only, not the primary readout; resolving success on the Part 1 primary-endpoint result
- — · resolved · resolved_at · — → 2026-09-21 · verified against the primary 6-K (2026-06-02, accession 0001193125-26-252360): obefazimod met the FDA primary endpoint of placebo-adjusted clinical remission at Week 44 in both the 25mg (p<0.0001) and 50mg (p<0.0001) arms of ABTECT Part 1; June 29 6-K (Part 2) reports exploratory non-responder/relapser data only, not the primary readout; resolving success on the Part 1 primary-endpoint result
- — · resolved · resolution_state · date_passed → resolved · verified against the primary 6-K (2026-06-02, accession 0001193125-26-252360): obefazimod met the FDA primary endpoint of placebo-adjusted clinical remission at Week 44 in both the 25mg (p<0.0001) and 50mg (p<0.0001) arms of ABTECT Part 1; June 29 6-K (Part 2) reports exploratory non-responder/relapser data only, not the primary readout; resolving success on the Part 1 primary-endpoint result
This is a dated event and its evidence, not a forecast of its outcome. No price, implied move or market probability is collected or shown anywhere on this page.
